164 related articles for article (PubMed ID: 34235275)
1. Vaccine-enhanced disease: case studies and ethical implications for research and public health.
Jamrozik E; Heriot G; Bull S; Parker M;
Wellcome Open Res; 2021; 6():154. PubMed ID: 34235275
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.
Yang J; Ma C; Zhao Y; Fan A; Zou X; Pan Z
J Virol; 2020 Jun; 94(13):. PubMed ID: 32321805
[TBL] [Abstract][Full Text] [Related]
3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
4. Weighing the risks and benefits of vaccination.
Glickman LT
Adv Vet Med; 1999; 41():701-13. PubMed ID: 9890055
[TBL] [Abstract][Full Text] [Related]
5. Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs.
Dans AL; Dans LF; Lansang MAD; Silvestre MAA; Guyatt GH
J Clin Epidemiol; 2018 Mar; 95():137-139. PubMed ID: 29180056
[TBL] [Abstract][Full Text] [Related]
6. Vaccine hesitancy and trust. Ethical aspects of risk communication.
Nihlén Fahlquist J
Scand J Public Health; 2018 Mar; 46(2):182-188. PubMed ID: 28847220
[TBL] [Abstract][Full Text] [Related]
7. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
Smith TRF; Schultheis K; Broderick KE
Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
[TBL] [Abstract][Full Text] [Related]
8. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
Wattigney WA; Mootrey GT; Braun MM; Chen RT
Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
[TBL] [Abstract][Full Text] [Related]
10. Vaccination against acute respiratory virus infections and measles in man.
Osterhaus AD; de Vries P
Immunobiology; 1992 Feb; 184(2-3):180-92. PubMed ID: 1587542
[TBL] [Abstract][Full Text] [Related]
11. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
12. Allergic reactions to Japanese encephalitis vaccine.
Plesner AM
Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
[TBL] [Abstract][Full Text] [Related]
13. Ontology-Based Vaccine Adverse Event Representation and Analysis.
Xie J; He Y
Adv Exp Med Biol; 2017; 1028():89-103. PubMed ID: 29058218
[TBL] [Abstract][Full Text] [Related]
14. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
15. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
[TBL] [Abstract][Full Text] [Related]
16. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
17. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
Palatnik-de-Sousa CB; Nico D
Front Immunol; 2020; 11():204. PubMed ID: 32210953
[TBL] [Abstract][Full Text] [Related]
18. A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease.
Li C; Zhou X; Zhong Y; Li C; Dong A; He Z; Zhang S; Wang B
J Immunol; 2016 Feb; 196(4):1721-31. PubMed ID: 26792805
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
